Clinical trial
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV…
NCT00329641 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00329641 |
|---|---|
| Title | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye |
| Official title | Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel, sorafenib tosylate |
| Enrollment | 25 |
| Start date | Feb 1, 2011 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | May 25, 2006 |
| Last update posted | Jul 31, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: